InnoCan Pharma Statistics

Total Valuation

InnoCan Pharma has a market cap or net worth of CAD 64.33 million. The enterprise value is 60.24 million.

Market Cap	64.33M
Enterprise Value	60.24M

Important Dates

The next estimated earnings date is Tuesday, August 12, 2025.

Earnings Date	Aug 12, 2025
Ex-Dividend Date	n/a

Share Statistics

InnoCan Pharma has 292.42 million shares outstanding. The number of shares has increased by 8.94% in one year.

Current Share Class	292.42M
Shares Outstanding	292.42M
Shares Change (YoY)	+8.94%
Shares Change (QoQ)	+1.15%
Owned by Insiders (%)	3.90%
Owned by Institutions (%)	0.18%
Float	226.12M

Valuation Ratios

PE Ratio	n/a
Forward PE	n/a
PS Ratio	1.47
PB Ratio	6.50
P/TBV Ratio	9.56
P/FCF Ratio	n/a
P/OCF Ratio	n/a
PEG Ratio	n/a

Financial Ratio History

Enterprise Valuation

The stock's EV/EBITDA ratio is 85.70, with an EV/FCF ratio of -86.95.

EV / Earnings	-64.58
EV / Sales	1.38
EV / EBITDA	85.70
EV / EBIT	92.31
EV / FCF	-86.95

Financial Position

The company has a current ratio of 4.08, with a Debt / Equity ratio of 0.19.

Current Ratio	4.08
Quick Ratio	2.84
Debt / Equity	0.19
Debt / EBITDA	2.68
Debt / FCF	-2.72
Interest Coverage	90.80

Financial Efficiency

Return on equity (ROE) is 16.61% and return on invested capital (ROIC) is 4.40%.

Return on Equity (ROE)	16.61%
Return on Assets (ROA)	2.86%
Return on Invested Capital (ROIC)	4.40%
Return on Capital Employed (ROCE)	5.54%
Revenue Per Employee	n/a
Profits Per Employee	n/a
Employee Count	n/a
Asset Turnover	3.07
Inventory Turnover	1.14

Taxes

In the past 12 months, InnoCan Pharma has paid 1.74 million in taxes.

Income Tax	1.74M
Effective Tax Rate	55.66%

Stock Price Statistics

The stock price has decreased by -10.00% in the last 52 weeks. The beta is -0.29, so InnoCan Pharma's price volatility has been lower than the market average.

Beta (5Y)	-0.29
52-Week Price Change	-10.00%
50-Day Moving Average	0.18
200-Day Moving Average	0.20
Relative Strength Index (RSI)	67.00
Average Volume (20 Days)	59,039

Short Selling Information

Short Interest	n/a
Short Previous Month	n/a
Short % of Shares Out	n/a
Short % of Float	n/a
Short Ratio (days to cover)	n/a

Income Statement

In the last 12 months, InnoCan Pharma had revenue of CAD 43.79 million and -932,840 in losses. Loss per share was -0.00.

Revenue	43.79M
Gross Profit	39.24M
Operating Income	652,557
Pretax Income	3.12M
Net Income	-932,840
EBITDA	702,864
EBIT	652,557
Loss Per Share	-0.00

Full Income Statement

Balance Sheet

The company has 9.15 million in cash and 1.88 million in debt, giving a net cash position of 7.27 million or 0.02 per share.

Cash & Cash Equivalents	9.15M
Total Debt	1.88M
Net Cash	7.27M
Net Cash Per Share	0.02
Equity (Book Value)	9.90M
Book Value Per Share	0.02
Working Capital	11.62M

Full Balance Sheet

Cash Flow

In the last 12 months, operating cash flow was -666,930 and capital expenditures -25,872, giving a free cash flow of -692,802.

Operating Cash Flow	-666,930
Capital Expenditures	-25,872
Free Cash Flow	-692,802
FCF Per Share	-0.00

Full Cash Flow Statement

Margins

Gross margin is 89.61%, with operating and profit margins of 1.49% and -2.13%.

Gross Margin	89.61%
Operating Margin	1.49%
Pretax Margin	7.13%
Profit Margin	-2.13%
EBITDA Margin	1.61%
EBIT Margin	1.49%
FCF Margin	n/a

Dividends & Yields

InnoCan Pharma does not appear to pay any dividends at this time.

Dividend Per Share	n/a
Dividend Yield	n/a
Dividend Growth (YoY)	n/a
Years of Dividend Growth	n/a
Payout Ratio	n/a
Buyback Yield	-8.94%
Shareholder Yield	n/a
Earnings Yield	-1.45%
FCF Yield	-1.08%

Fair Value

There are several formulas that can be used to estimate the intrinsic value of a stock.

Lynch Fair Value	n/a
Lynch Upside	n/a
Graham Number	n/a
Graham Upside	n/a

Stock Splits

This stock does not have any record of stock splits.

Last Split Date	n/a
Split Type	n/a
Split Ratio	n/a

Scores

InnoCan Pharma has an Altman Z-Score of 6.59 and a Piotroski F-Score of 5.

Altman Z-Score	6.59
Piotroski F-Score	5